Kornimate/medical-research-clean huggingface dataset:
youth power action feasibility study of online support group intervention among adolescents living with hiv in nigeria

Conditions: HIV/AIDS; Adolescent Behavior; Medication Adherence; Health Behavior

Summary: this study will examine the feasibility and acceptability of an intervention designed to improve retention in hiv care services and improve anti-retroviral therapy (art) adherence among adolescents ages 15-19 years living with hiv enrolled in art services.

study aim is to examine the feasibility and acceptability of an intervention designed to improve retention in hiv care services and improve anti-retroviral therapy (art) adherence among adolescents ages 15-19 years living with hiv enrolled in art services. a single group, pre/posttest design including structured questionnaires with adolescents living with hiv. additionally, we will abstract clinical data from the medical record system. we will also conduct in-depth interviews with a subset of participants, as well as health care staff who are engaged in the intervention, at endline. the objectives of this study are: 1. to examine the feasibility of implementing a mobile/electronic health (m/ehealth) intervention designed to improve retention in hiv care services and art adherence among alhiv ages 15-19 years through an online support group (using facebook). 2. to assess acceptability of and engagement in the intervention by the target audience to inform improvements to the intervention. 3. to gather preliminary data on the psycho-social and health-related outcomes that the intervention is designed to affect to inform an outcome evaluation study that will be conducted following the conclusion of the feasibility study. 4. to collect information on recruitment, informed consent and data collection processes to inform the outcome evaluation study of the current intervention that will be conducted once findings from this feasibility study are incorporated into the intervention design.

Eligibility criteria:
inclusion criteria: * hiv positive and currently on art for at least 6 months * age 15 to 19 years * can demonstrate basic literacy necessary to participate in online chats exclusion criteria: * not planning to remain in the study area (within akwa ibom state) for the duration of the study (approximately 6 months) * currently enrolled in an in-person support group * currently enrolled in another research study related to hiv service retention or art adherence * critically or severely ill requiring hospitalization or such that the individual is unable to provide informed consent at the time of study recruitment
cteph predictors following acute pulmonary embolism

Conditions: CTEPH Predictors

Summary: identify risk factors for developing chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. determine echocardiographic predictors of chronic thromboembolic pulmonary hypertension. determine the radiological predictors of chronic thromboembolic pulmonary hypertension in ct pulmonary angiography.

chronic thromboembolic pulmonary hypertension(cteph) is considered to be a long-term complication after acute pulmonary embolism (pe) characterized by persistent perfusion defects of pulmonary arteries caused by fibrotic remodeling. its pathophysiology has not been fully elucidated yet, although it has been accepted that the increased pulmonary vascular resistance is caused by obstruction of pulmonary arterial vessels by organized thromboemboli and by vascular remodeling of small un obstructed vessels. (1) although cteph had been thought to develop in relatively few patients post-pulmonary thromboembolism, the latest data suggest an unexpectedly high incidence of approximately 4%. (2) in addition, although there are well-defined risk factors for pulmonary thromboembolism, the risk factors for cteph have not yet been sufficiently defined. (3) for that reason, the determination of risk factors is of great importance for the early diagnosis of patients with cteph, with its high mortality and morbidity. the clinical presentation of cteph is characterized by non-specific symptoms and include exercise intolerance, dyspnea, fatigue, chest pain, and syncope (at exercise). these symptoms are also consistent with other more common cardiopulmonary conditions such as asthma, chronic obstructive pulmonary disease (copd), interstitial lung disease, coronary artery disease, cardiac arrhythmia or heart failure not caused by chronic pulmonary thrombi. (4) these non-specific symptoms are commonly reported by patients who suffered from an acute pe and therefore, the possibility of cteph can be frequently considered . the diagnostic management of cteph is complex. in many patients pulmonary perfusion scintigraphy, transthoracic echocardiography and conventional pulmonary angiography with determination of pulmonary hemodynamics need to be performed before the diagnosis of cteph can be refuted. (5)

Eligibility criteria:
inclusion criteria: all adult patients of both gender more than 18 yrs admitted at chest department and diagnosed by ct pulmonary angiography as acute pulmonary embolism during a period of one year will be recruited in the study. about 80 patients as the average number of patients admitted per month is 7. exclusion criteria: patients with congenital or acquired heart diseases. patients with chronic chest diseases. patients previously diagnosed chronic thromboembolic pulmonary hypertension by v/q scan.
gut microbiota post roux-en-y gastric bypass surgery

Conditions: Obesity

Summary: the purpose of this study is to investigate mechanisms responsible for weight change in patients who have undergone weight loss surgery. specifically, we will compare the gut microbiota, plasma bile acids, plasma gut peptides (glp-1, glp-2, and pyy), and plasma lps in three groups of subjects: 3-5 years post gastric bypass patients who experienced sub-optimal weight loss, 3-5 years post gastric bypass patients who had successful weight loss, and a control group who has not had a weight loss surgery and are of similar age, gender, body mass index as the gastric bypass groups.


Eligibility criteria:
inclusion criteria: * female * age 18-65 * 3-5 years post roux-en-y gastric bypass and experienced successful weight loss following surgery (up to n=10) or * 3-5 years post roux-en-y gastric bypass and did not experience optimal weight loss following surgery (up to n=10) or * nonsurgical control participants who are approximately matched in sex, age, and bmi to the optimal weight loss group (up to n=10). exclusion criteria: * tobacco use in past three months. * taking a medication which is known to significantly influence gastrointestinal transit time or affect the microbiome or other variables significantly (as determined by study pharmacist/md). * history of diabetes mellitus. * has taken an oral or iv/im antibiotic in the past 3 months. * has taken probiotic and/or prebiotic agent in the past 3 months * history of significant intestinal disease or disorder (e.g., crohn's disease, ulcerative colitis, irritable bowel syndrome) * history of gastrointestinal surgery that may impact measures of biological variables, as determined by the investigator. * medical condition expected to impact the biological variables of interest or interfere with providing a sample, as determined by the investigator. * unable to speak/read english. * breastfeeding, pregnant, or planning to become pregnant within the duration of the study. * unwilling to use a medically acceptable form of contraception. * history of bipolar or psychotic spectrum disorder or alcohol or substance treatment in the past year

Keywords: gut microbiota weight regain gastric bypass
study of the early occurrence of hepatocellular carcinoma (hcc) in egyptian hcv infected patients receiving sofosbuvir and daclatasvir

Conditions: Hepatitis C

Summary: to evaluate the early detection of hcc in patients taking sofosbuvir and daclatasvir.

methodology: design: prospective, randomized study used to detect early incidence of hcc in patients taking sofosbuvir and daclatasvir to treat hcv. patients will be recruited from the national hepatology and tropical medicine research institute (nhtmri) duration of study: 24 weeks from starting the daas methods: patients will go through examination and lab. workup three times in this study: * first time: * before starting antiviral therapy, all included patients will undergo through physical examination, lab workup including hcv-rna quantitative, fasting plasma glucose or hba1c if diabetic, serum creatinine, cbc, ast, alt, prothrombin concentration or inr, total bilirubin, serum albumin, pregnancy test ( ladies in child bearing period), afp as a marker of hcc. * included patients will also undergo through diagnostic procedures as abdominal ultrasonography and ecg (men \>40, women\>50). * second time: * at the end of antiviral therapy (12 weeks), virological response to therapy will be assessed by quantitative hcv rna detection, using pcr. * patients will lab workup including , fasting plasma glucose or hba1c if diabetic, serum creatinine, cbc, ast, alt, prothrombin concentration or inr, total bilirubin, serum albumin, afp as a marker of hcc. * the abdominal ultrasonography will be repeated any suspected focal lesion of the liver will be evaluated with triphasic ct scan or mri to assess the occurrence or the recurrence of hcc. * third and last time: * at 24 weeks ( patients will be off treatment for the previous 12 weeks) , virological response to therapy will be assessed by quantitative hcv rna detection, using pcr. * patients will lab workup including, fasting plasma glucose or hba1c if diabetic, serum creatinine, cbc, ast, alt, prothrombin concentration or inr, total bilirubin, serum albumin, afp as a marker of hcc. * the abdominal ultrasonography will be repeated any suspected focal lesion of the liver will be evaluated with triphasic ct scan or mri to assess the occurrence or the recurrence of hcc.

Eligibility criteria:
inclusion criteria: * patients have positive hcv-rna and taking daas to treat it. * both sexes will be included * age above 18 to 75 years old * child pugh score ( a and b ) exclusion criteria: * total serum bilirubin\<3 mg/dl * serum albumin \> 2.8 g/dl * inr≥ 1.7 * platelet count\< 50000/mm3 if any of the above criteria is not caused by liver disease, the patient can be included in the study. * hcc, except 4 weeks after intervention aiming at cure with no evidence of activity by dynamic imaging (ct or mri). * extra- hepatic malignancy. * pregnancy or inability to use effective contraception. * inadequately controlled diabetes mellitus (hba1c\>9%).

Keywords: daclatasvir hcc hcv sofosbuvir
the six minute walk test: influence of instruction on results

Conditions: Interstitial Lung Disease

Summary: two - four 6mwt performed according to ats standards. each walk however had specifically altered wording and coaching performed in random order to determine differences in outcomes. one walk was done in the standard ats fashion. one was done coaching to walk as fast as the patient can walk. one was coached to walk at the patients normal walking pace. one was coached to walk at the patient's leisure walking pace.

alternate 6mwt where subjects will be asked to walk as fast as they can, walk as normal as they can and walk leisurely as they can in 6 minutes compared to standard of care 6mwt which is walk as far as you can in 6 minutes.

Eligibility criteria:
inclusion criteria: * advanced lung disease such as copd, ild, ipf, or pah exclusion criteria: * inability to walk, requiring supplemental oxygen, cardiac disease preventing successful 6mwt

Keywords: 6 minute walk test idiopathic pulmonary fibrosis pulmonary arterial hypertension
australian ucsf concussion in athletes

Conditions: Concussion, Mild

Summary: analysis of cardiac induced brain forces using cranial accelerometry has been shown to diagnose concussion in high school athletes. this trial expands on this observation by recording headpulse signals in a recently concussed athletes playing australian rules football.

recently concussed athletes will have headpulse measurements obtained as soon after the clinically identified concussion as is feasible and at 1-3 day intervals over the course of a month. these recordings will pair with a self administered neurological symptom inventory (nsi) to track the athletes subjective concussion symptoms. data will be used to confirm prior models of analysis and produce a tool to be confirmed in a future study.

Eligibility criteria:
concussion subjects: inclusion criteria: * diagnosed with sport related concussion * first recording obtained within one week * willingness to have multiple recordings in the month following concussion exclusions: - head laceration control subjects: inclusion criteria: * athletes without concussion over the last year * willingness to have single or multiple recordings exclusion criteria: - head laceration

Keywords: mild traumatic brain injury
breast 3dus abus system comparison

Conditions: Breast Diseases

Summary: this comparative study will recruit 30 females who are scheduled for mammography and ultrasound assessment. the clinical 2d ultrasound is performed routinely, and the research portion of this study will add a few extra 3-d ultrasound images during the procedure. the ultrasound imaging laboratory under the direction of dr. aaron fenster has developed a customized device designed to acquire 3d ultrasound of the breast using a commercial ultrasound machine. the purpose is to see how well 3-dimensional ultrasound acquire from that device is able to visualize tumours and other key features in comparison to the clinical system inveniatm developed by ge medical.


Eligibility criteria:
inclusion criteria: * adult patients who are scheduled for screening abus * adults patients who are scheduled for short term follow-up with abus. * must be at least 18 years of age or older. * must be proficient in english (reading/writing). exclusion criteria: * patients with breast implants. * patients with contraindication for abus. * patients who cannot tolerate abus.

Keywords: 3d ultrasound intervention
a device for screening of fall risk in the elderly

Conditions: Postural Imbalance; Gait, Unsteady

Summary: this study evaluates the screening accuracy of a device (oak) in assessing fall risk in the elderly, compared to the assessment provided by the algorithm for fall risk assessment of the centers for disease control and prevention (cdc). the oak device is a technologic system, based on virtual reality. it allows to quickly perform a fall risk assessment integrating clinical indexes of the brief-bestest (the balance evaluation system test), and kinematic and posturgraphic indexes. the participants interact with the oak device through simple exercises, then the device provides an assessment of their functional mobility, equilibrium and postural reactions.

falls are a serious problem among the elderly. most falls do not cause death, but 20%-30% of falls result in serious injuries representing a significant source of morbidity and mortality. good evidence shows that many falls can be prevented. thus, identifying people with risk of falling is crucial. the aim of this study is the evaluation of the screening accuracy of a device (oak) in assessing fall risk in the elderly. participants are recruited at irccs galeazzi orthopedic hospital in milan, among outpatients and healthy volunteers. a brief questionnaire is administered in order to collect data relevant to the cdc algorithm for fall risk assessment. then, participants are assessed through the oak device. the oak assessment is evaluated in terms of performance, accuracy (in comparison to the cdc algorithm for fall risk assessment) and safety.

Eligibility criteria:
inclusion criteria: * able to walk without walking aids. * signed informed consent. exclusion criteria: * neurological, musculoskeletal and orthopaedic disorders limiting mobility function and equilibrium. psychiatric disorders. any other medical condition limiting mobility function, as diabetes, obesity, serious ocular disorders (e.g. glaucoma), vestibular disorders (e.g. labyrinthitis) and proprioceptive disorders (e.g. ataxia). * pacemaker. * surgical interventions for orthopaedic disorders (e.g. knee or hip prosthesis) during the previous 6 months. * drug intake altering coordination and equilibrium (e.g. anti-epileptic, sedative-hypnotic drugs). * pregnancy.

Keywords: accidental falls risk assessment frail elderly
positron emission tomography (pet)-scan in the evaluation of high tumor burden follicular lymphoma

Conditions: Lymphoma, Follicular

Summary: the purpose of the study is to assess in a prospective series of patients with high tumor burden follicular lymphoma treated with r-chop, the predictive value of \[18f\]-fdg pet performed over (after 4 treatments), and at the end of the first-line treatment on progression-free survival at 2 years.


Eligibility criteria:
inclusion criteria: * patients with malignant non-hodgkin follicular lymphoma (histologic grade 1 to 3 in the who classification), histologically confirmed, * patients who have not previously been treated for this disease, * introducing one of the criteria for high tumor burden, * patients aged over 18 and under 80 years, * patients whose ecog condition is ≤ 2, * patients whose haematological functions are adequate within 28 days preceding the treatment (hemoglobin ≥8,0g/dl; neutrophils ≥1,5e-9/l, platelets ≥100e-9/l), * patient had the pet examination less than a month before the start of chemotherapy. exclusion criteria: * patients with lymphoma who have already transformed or been treated for this disease, * patients whose lymphoma is stage 3b, * patients with impaired central nervous system, * patients regularly taking corticosteroids during the 4 weeks preceding the treatment (unless the dose administered is equivalent to ≤20 mg/day prednisone). * patients who have undergone major surgery during the 28 days preceding the inclusion, * patients with low kidney and/or liver function, * patients with hiv + or had an infection with hbv or hcv less than 4 weeks. patients with hepatitis b serology is positive unless the sign is related to vaccination, * patients whose life expectancy ≤ 6 months, * patients sensitive or allergic to murine products, * patients who participated in another clinical trial during the 30 days preceding the recording, * patients with other medical problems or psychological succeptibles interfere with the study, * patients under adult supervision.

Keywords: follicular lymphoma pet gela
feasibility evaluation - blood glucose level monitoring by microwave metamaterial sensor in blood samples.

Conditions: Diabetes

Summary: the goal of this clinical trial is to test microwave metamaterial glucose sensor on blood samples. it means to compare the results of glucose values obtained by microwave metamaterial sensor and by standard biochemical analyzer.

participants will include physiological and pathological populations. participants donate approximately 5 ml of blood sample. three sample tubes will be collected from ten adult participants. in the first test tube, the blood glucose content will be determined by a validated biochemical analyzer (roche, switzerland). in the remaining volume of the blood sample, the dielectric parameters (relative permittivity and conductivity) will be estimated using a coaxial probe (keysight, usa). microwave metamaterial sensors with 5, 7 and 9 unit cells will be loaded with blood samples and the specific scattering matrices will be obtained using a vector network analyzer. the main monitored outcome measure will be the phase of parameter s21.

Eligibility criteria:
inclusion criteria: * blood glucose can be measured with standard biochemical analyzer exclusion criteria: * minimum age limit 18 years

Keywords: diabetes
yes/no questionnaire for aphasic patients (ynq)

Conditions: Stroke, Acute; Aphasia

Summary: quality of care depends strongly on oral communication with patients. stroke patients, who have language disorders, have understanding difficulties, but also have difficulties in expressing their needs and in being understood. available tools do not allow a professional consensus on the assessment of patients' ability to answer reliably to questions asked by caregivers. the investigators propose an answer reliability assessment tool based on yes or no questions. the goal of the present study is to define an optimal score for defining the test positivity, as a compromise between sensitivity and specificity, and by emphasizing the negative predictive value.

in france, about 130,000 persons per year are victims of stroke. thirty percent of the victims suffer from aphasia during the acute phase. these language impairments have an impact on caregiving. in the context of post-stroke aphasia, the most relevant means of verbal communication is closed-ended questioning. however, the available tools do not allow a professional consensus and the comprehensive assessment tools for aphasia do not provide any indication of the reliability of patients' answers. the investigators have developed a tool, the yes/no questionnaire that consists of 10 closed-ended questions designed to assess the patient's ability to provide a coherent answer. during one year, successive patients taken care in the neurovascular unit at la rochelle hospital will be assessed for eligibility to the study and their relative will be informed and ask for consent. aphasic patients will therefore answer the yes/no questionnaire. based on the speech therapist evaluation, patients will be classified as "reliable respondent" or "unreliable respondent".

Eligibility criteria:
inclusion criteria: * over 18 years old * left-sided stroke * right-handed * mother language: french * hospitalized in neurovascular unit or neurology department * nihss score over 25 exclusion criteria: * deaf * psychiatric history * stroke history * dementia or pre-stroke cognitive impairment * under guardianship * refusal to participate (relatives)
vaginal dinoprostone versus isonicotinic acid hydrazide prior to diagnostic office hysteroscopy

Conditions: Postmenopausal Bleeding

Summary: to compare the effectiveness of vaginal dinoprostone and vaginal isonicotinic acid hydrazide in minimizing the pain experienced by postmenopausal patients during diagnostic ofﬁce hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. cervical ripening is made possible by the use of medication through different routes.

Eligibility criteria:
inclusion criteria: * menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding or abnormal ultrasound ﬁndings) exclusion criteria: * nulliparous patients * patients with cervical pathology * retroverted uterus (detected by transvaginal ultrasound) * previous cervical surgery * patients with severe vaginal bleeding * allergy or contraindications to dinoprostone or inh therapy